The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retracted: Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Paola Queirolo
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma Advanced Research Company
Travel, Accommodations, Expenses - MSD Oncology; Sanofi/Regeneron
 
Ana Maria Abajo Guijarro
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Youyou Hu
Employment - Galderma; Roche
 
Dao Wang
Employment - F. Hoffmann LaRoche
 
Sergio Jobim Azevedo
No Relationships to Disclose
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Vanna Chiarion -Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Paolo Pronzato
No Relationships to Disclose
 
Francesco Spagnolo
Honoraria - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - MSD; Novartis; Philogen; Pierre Fabre; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Karmele Mujika
No Relationships to Disclose
 
Gabriella Liszkay
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; MSD; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology (Inst); Sanofi
Research Funding - Inscite Corporation (Inst); Novartis (Inst); Roche
 
Luis de la Cruz Merino
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; MSD Oncology; Novartis; Roche
Research Funding - Celgene (Inst); Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Hussein A. Tawbi
Consulting or Advisory Role - Array BioPharma; Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)